Invention Grant
- Patent Title: Use of acetylated tubulin as a biomarker of drug response to furazanobenzimidazoles
-
Application No.: US15294157Application Date: 2016-10-14
-
Publication No.: US10067120B2Publication Date: 2018-09-04
- Inventor: Heidi Alexandra Lane , Felix Bachmann
- Applicant: Basilea Pharmaceutica AG
- Applicant Address: CH Basel
- Assignee: BASILEA PHARMACEUTICA AG
- Current Assignee: BASILEA PHARMACEUTICA AG
- Current Assignee Address: CH Basel
- Priority: EP11155774 20110224
- Main IPC: A61K31/415
- IPC: A61K31/415 ; A61K31/41 ; G01N33/50 ; A61K31/42 ; A61K31/4184 ; A61K31/4245 ; G01N33/68
Abstract:
Use of acetylated tubulin as a biomarker for predicting the response to a compound, preferably resistance of a disease such as cancer in a subject to said compound, wherein the compound is a furazanobenzimidazoles compound of general formula (I).
Public/Granted literature
- US20170122934A1 USE OF ACETYLATED TUBULIN AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES Public/Granted day:2017-05-04
Information query
